XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3
BASIS OF PRESENTATION (Details Narrative) - USD ($)
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Net loss $ (6,639,935) $ (4,790,597)            
Amortization of right-of-use assets 22,507 102,549            
Accumulated deficit $ (104,479,192)       $ (91,644,233)      
Description of the warrants and reduced the exercise price which the Company issued 9,748,252 new warrants and reduced the exercise price of 4,874,126 warrant shares from $1.45 to $0.8701 to induce exercise and receive gross cash proceeds of $4,240,977              
Stockholders' equity $ 34,976,599 $ 44,195,740 $ 32,119,574 $ 34,546,682 $ 36,043,028 $ 43,669,058 $ 44,007,783 $ 39,284,295
CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]                
Net cash used in operations 3,883,215              
Working capital 11,027,653              
Amortization of right-of-use assets 1,588,163              
Cash proceed $ 629,426              
Proceeds from sale of common stock 901,488